Battling COVID-19: using old weapons for a new enemyReview Published on 2020-05-202022-10-28 Journal: Tropical Diseases, Travel Medicine and Vaccines [Category] COVID-19, [키워드] COVID-19 drug evaluate evaluated Hydroxychloroquine In-vitro in-vivo efficacy Lopinavir/ritonavir management Middle East MOST nitazoxanide pandemic proportions Randomized controlled trials reached related virus remdisivir respiratory SARS-CoV-2 Tocilizumab Treatment [DOI] 10.1186/s40794-020-00107-1 PMC 바로가기 [Article Type] Review
Effective treatment of severe COVID-19 patients with tocilizumab530 Published on 2020-05-192022-10-29 Journal: Proceedings of the National Academy of Sciences of [Category] COVID-19, MERS, SARS, [키워드] absorbed activated addition Adverse reaction analyzed average binding C-reactive protein change China clinical manifestations Clinical outcome Computerized tomography coronavirus disease COVID-19 Critical critical COVID-19 patients CT scan cytokine Cytokine storm diagnosed discharged effective Efficacy elevated high affinity humanized IL-6 IL-6 receptor immune immune characteristics inflammatory monocyte Inflammatory response Inflammatory responses inflammatory storm interleukin-6 Laboratory lung lymphocyte manifested monoclonal antibody mononuclear macrophage organs other tissue oxygen Oxygen therapy pathogenic Pathways Patient Peripheral blood producing receptor reduce mortality returned SARS-CoV-2 Science second secreting severe coronavirus disease severe COVID-19 patient Severe patient Significance significantly Symptom T cell T lymphocyte target target cells technology the cytokine storm therapeutic strategy therapy Tocilizumab Treatment university were given with COVID-19 [DOI] 10.1073/pnas.2005615117 PMC 바로가기 [Article Type] 530
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patientsOriginal Article Published on 2020-05-152024-09-04 Journal: Rheumatology Advances in Practice [Category] 대상포진, [키워드] fluorodeoxyglucose-PET/CT giant cell arteritis Large vessel vasculitis Tocilizumab [DOI] 10.1093/rap/rkaa017 PMC 바로가기 [Article Type] Original Article
COVID-19 pandemic: an overview of epidemiology, parthenogenesis, diagnostics and potential vaccines and therapeuticsReview Published on 2020-05-132022-10-28 Journal: Therapeutic Delivery [Category] COVID-19, SARS, [키워드] Abstract against SARS-CoV antimalarial antivirals bevacizumab clinical evaluation clinical therapy coronavirus COVID-19 death diagnostics Epidemic Epidemiology evaluated Favipiravir FDA-approved drug Genetic highlight Hydroxychloroquine immunomodulator Infection Middle East pandemic Patient preventive measures recent Remdesivir repurposed therapies Respiratory Coronavirus SARS-CoV SARS-CoV-2 shown similarity syndrome Tocilizumab Vaccine Vaccine development viruses [DOI] 10.4155/tde-2020-0035 PMC 바로가기 [Article Type] Review
Tocilizumab for the treatment of severe coronavirus disease 2019Research Article Published on 2020-05-102022-10-04 Journal: Journal of medical virology [Category] 진단, 치료제, [키워드] adverse event Antiviral agents cardiovascular disease Chronic kidney disease contribute coronavirus cough COVID‐19 COVID‐19 declined Diabetes Mellitus died discharged Dyspnea IL‐6 immune response improve clinical outcomes Inflammatory inflammatory markers inhibitor intensive care interquartile range invasive ventilation limitations majority male manifestation median median age oral temperature Pathogenesis Patient presenting symptoms proportion radiological improvement Randomized controlled trials reduced retrospective SARS‐CoV‐2 severe coronavirus disease Support Tocilizumab tocilizumab therapy Treatment Ventilation ventilatory support [DOI] 10.1002/jmv.25964 PMC 바로가기 [Article Type] Research Article
Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)Article Published on 2020-05-092022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] 95% CI Administered administration adverse event Affect alanine aminotransferase ALT Cohort Combination conducted COVID-19 COVID-19 pneumonia Critically ill patient CRP diagnosed with COVID-19 diagnosis of COVID-19 did not reduce dose enrolled female first dose Hospitalized Hydroxychloroquine ICU ICU admission INR International intravenously IRCCS Italy laboratory data laboratory measure lymphocyte male Matteo median age mortality rate normalized off label therapy outcome Patient patients patients evaluated patients treated Pavia Platelet Pneumonia propensity score matching prophylactic dose repeated reported Result Retrospective analysis secondary Severe COVID-19 pneumonia Side effect significant interaction significantly Standard TCZ therapy Tocilizumab Treatment with COVID-19 [DOI] 10.3390/microorganisms8050695 PMC 바로가기 [Article Type] Article
Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and AutoimmunityReview Published on 2020-05-082022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS, [키워드] accompanied Antiviral approach Autoimmunity balance Baricitinib China close monitoring complex cough COVID-19 CRS Cytokine release syndrome disease Dyspnea Effectiveness fatigue Features Fever flu-like symptom health emergency Host Hydroxychloroquine immunomodulation Immunosuppressant immunosuppressive agent increase in induce Infection infection risk initiated life-threatening manifestation New Novel coronavirus Patient patients patients with COVID-19 pro-inflammatory response receiving Release researcher Rheumatic diseases rheumatoid arthritis SARS-CoV-2 scenario sequenced serological severe interstitial pneumonia Spread therapy Tocilizumab Treatment trials Typical [DOI] 10.3390/ijms21093330 PMC 바로가기 [Article Type] Review
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in SwitzerlandOriginal article Published on 2020-05-052024-09-04 Journal: RMD open [Category] 대상포진, [키워드] abatacept biological therapies comparative effectiveness research rheumatoid arthritis Tocilizumab tumour necrosis alpha inhibitors [DOI] 10.1136/rmdopen-2020-001174 PMC 바로가기 [Article Type] Original article
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventionsArticle Published on 2020-05-042023-06-15 Journal: Autoimmunity reviews [Category] MERS, SARS, [키워드] Anakinra COVID-19 Cytokine storm IL-1 IL-6 SARS-CoV2 Tocilizumab type-I interferon [DOI] 10.1016/j.autrev.2020.102567 PMC 바로가기 [Article Type] Article
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical ResearchReview Article Published on 2020-05-032023-07-01 Journal: In vivo (Athens, Greece) [Category] SARS, [키워드] antiviral drugs Coronaviruses COVID-19 review SARS-CoV-2 Tocilizumab virus [DOI] 10.21873/invivo.11949 PMC 바로가기 [Article Type] Review Article